I´m currently trying to determine the ic50 of enzalutamide in several cancer cell lines. But i have many doubts and currently i´m the only one working with this kind of assays in my department.
The workflow i am using is the next one:
1. Thaw the cells and grow them in media with 10% FBS
2. Detach them using trypsin (5 min at 37°C) when cells are around 50-70% confluence.
3. Seed 2000 or 3000 cells per well (depending on the size of these) and incubate for 24 hours at 37°C
4. Treatment of the cells with 5 different concentrations of enzalutamide (0.1,1,10,100 and 300 uM) in triplicates and considering 2 controls (DMSO and media).
5. Previously i was using incubation periods (with treatment) of 24 hours, but my results where always very weird (lots of variance between replicates and low concentration treatments tend to increase the proliferation rate instead of decreasing it).
After getting these results i went into the Sanger Institute´s database (GDSC), and noticed that their reading where after a 72 hour period (with treatment) so i decided to use this approach of 72 hours and got better results (variance decrease and all treatment concentrations give values equal or below the negatives).
After this i got some questions:
1) How to determine how much time will i leave the cells with the treatment?
2) How frequently should i change the media (and thus the treatment) before reading? Once every 24 hours? Once every 48 hours? Never?
Several authors use different treatment periods (72, 96 and even one week) and I´ve been searching in similar works some answers for these questions but this kind of information is frequently ommited from the papers (even from the Supplementary material).
I´m currently using the Cyquant Direct Cell Proliferation Kit (DNA content and Fluoresence based growth inhibition assay). Readings in a microplate reader (96 wells). Readings are made from below the well.
Any help will be highly appreciated